GSK's gepotidacin shows 92.6% success in uncomplicated urogenital gonorrhoea phase three trial, matching leading combination therapy.

GSK reports positive results from a phase three trial of gepotidacin as an oral treatment for uncomplicated urogenital gonorrhoea. The treatment showed a 92.6% success rate, matching the leading combination therapy, and its safety profile was consistent with previous trials. Gonorrhoea, with 82 million new cases annually worldwide, sees increasing resistance to current therapies.